secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-032073
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q1 2026 net loss narrows to $13.5M; launches Atera platform
------------------------------------------------------------------------

- Revenue $150.8M (-3% YoY); +9% excluding $16.8M one-time license/royalty in Q1 2025.
- Gross margin 70% vs 68%; operating loss $17M vs $39.3M prior year.
- Net loss $13.5M vs $34.4M; cash $539.8M (+$112.9M YoY).
- Launched Atera spatial whole-transcriptome platform; shipping expected H2 2026.
- FY 2026 revenue guidance maintained at $600M-$625M (0-4% growth ex-2025 one-time).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000162828026032073/0001628280-26-032073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000162828026032073/txg-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer